Scynexis (SCYX) Cash from Investing Activities Growth (1y) (2014 - 2026)
Powered by 
Analysis
Scynexis (SCYX) Cash from Investing Activities Growth (1y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | -46.27% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -388.99% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 90.55% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 91.53% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -41.67% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | -157.08% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -6,635.44% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | -319.62% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -319.62% |
| Mar 31, 2026 | -104.22% |
| Dec 31, 2025 | -351.82% |
| Sep 30, 2025 | 539.72% |
| Jun 30, 2025 | 721.65% |
| Mar 31, 2025 | 128.09% |
| Dec 31, 2024 | -21.61% |
| Sep 30, 2024 | 107.37% |
| Jun 30, 2024 | 121.49% |
| Sep 30, 2023 | 3.79% |
| Sep 30, 2022 | -8,000.59% |
| Mar 31, 2022 | 95.50% |
| Sep 30, 2021 | -109.47% |
| Jun 30, 2021 | -100.48% |
| Mar 31, 2021 | 97.42% |
| Sep 30, 2020 | 948.22% |
| Jun 30, 2020 | 6.44% |
| Mar 31, 2020 | -217.66% |
| Dec 31, 2019 | 1,588.07% |
| Sep 30, 2019 | -102.82% |